MAPT and Alzheimer disease: Plasma levels of tau are reported as reliable biomarkers for AD pathology (Ashton et al., 2021; Palmqvist et al., 2020) with predictive capacity for future AD diagnosis (Lantero Rodriguez et al., 2020), and tau targeted treatments have also been explored, but with limited efficacy (Florian et al., 2023; Teng et al., 2022).